Episode Synopsis "S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)"

In this episode, Clinical Implications of Trophoblast-Cell Surface Antigen 2 in Non-Small Cell Lung Cancer, Dr. Justin Gainor and Dr. Helena Yu discusses the current diagnosis and treatment of non-small cell lung cancer as well as a new ADC target, trophoblast cell-surface antigen 2 or Trop2. Visit https://suiteweb.atpointofcare.com/#library/nsclc/2606.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

Listen "S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)"

More episodes of the podcast Hematology / Oncology @Point of Care Podcasts

• S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer
• S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits
• S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
• S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
• S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
• S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)
• S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC
• S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies
• S21:E1 – Improving Survival With HMA Maintenance Therapy in AML
• S21:E2 – Individualizing Care Plans for Patients With AML